Schrodinger (SDGR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Schrodinger

NasdaqGS•Healthcare•Health Information Services

$20.09-0.62(-0.03%)Market closed

Market Cap

$2.26B

P/S

8.7x

P/B

6.9x

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

How this company scores

AverageMetricSide Score: 54/100

Strongest: Profitability (17/25); weakest: Cash & Earnings Quality (5/25).

Profitability17/25

Growth17/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality5/25

Strengths

Long cash runwayInterest easily coveredProfit converts from growthConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 63.4x5y range 46.0x – 124.7x

Currently near its 4-quarter median.

P/S · 8.7x5y range 3.2x – 31.0x

Currently near its 20-quarter median.

P/B · 6.9x5y range 2.6x – 6.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.26B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $259.04M
Q. Revenue: $58.89M
TTM EBITDA: $-144.58M
TTM Op. Income: $-153.44M
Q. Op. Income: $-41.55M
TTM Net Income: $-54.34M
Q. Net Income: $5.97M
EPS: $0.08
Shares Out.: $74.71M

$259.04M in TTM revenue grew 8.9% YoY, reaching $58.89M last quarter. TTM EBITDA of $-144.58M and TTM operating income of $-153.44M show growth is flowing through to the bottom line. However, net income is negative at $54.34M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 9% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 55.1%
EBITDA Margin: -68.0%
Op. Margin: -70.6%
Net Margin: 10.1%

Op. margin of -70.6% is up 26.1% YoY — cost efficiency is improving. Net margin at 10.1% and gross margin of 55.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 27% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 8.7x
P/B Ratio: 6.9x

P/S of 8.7x and P/B of 6.9x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $640.39M
Cash: $287.85M
Long-Term Debt: N/A
Book Value: $328.96M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-34.07M
TTM Free Cash Flow: $-130.27M
FCF Margin: -50.3%
FCF / Net Income: 2.4

TTM FCF of $-130.27M on $-34.07M in operating cash flow. The FCF / Net Income ratio of 2.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 635% — an improving trend.